Navigation Links
Oxford BioMedica Announces Ocular Programme Update
Date:6/22/2011

s clinical study is breaking new ground as the first to directly administer a lentiviral vector-based treatment to patients in the US and the favourable safety profile of RetinoStat® is encouraging.  We continue to work closely with the regulatory bodies in order to advance our novel ocular programmes as rapidly as possible and, together with Sanofi, we look forward to further progress during 2011."

The second ocular product to enter clinical development is StarGen™, a novel gene-based treatment for Stargardt disease, and the first patient in the Phase I/IIa study was treated in the US in June 2011 at the Oregon Health & Science University's Casey Eye Institute.  StarGen™ has received European and US Orphan Drug Designation which brings development, regulatory and commercial benefits and, with no currently approved treatment, this novel product brings significant hope for the future to Stargardt patients.  The next product expected to enter Phase I/II clinical development is UshStat® for the treatment of Usher syndrome type 1B in H2 2011.  UshStat® has also received European and US Orphan Drug Designation.

"We are delighted to see Oxford BioMedica's lentiviral gene therapy products successfully moving into human studies,"said Stephen Rose, Ph.D., chief research officer of the Foundation Fighting Blindness, a US non-profit organisation that provided early funding for Oxford BioMedica's pre-clinical ocular programme. "The Company's innovative treatments hold great promise for saving vision in people affected by a broad range of devastating eye diseases for which current treatments are limited or non-existent."

Notes to editors

1. Oxford BioMedica®

Oxford BioMedica
'/>"/>

SOURCE Oxford Biomedica Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp.
2. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
3. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
4. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
5. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
6. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
7. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
8. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
9. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
10. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
11. Saladax Biomedical, Inc. Completes $9 Million Debt Financing With GE Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
... G rowth factor enhances ... stem cells , , BOSTON, July ... Boston have now laid the groundwork for regenerating heart tissue after a heart ... In the July 24 issue of Cell , they show that a ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... world-leading provider of scientific, technical and medical information ... a position statement by the European Menopause and ... on the topic of breast cancer screening. ... in women, with slightly more than ten percent ... is a well-established method to detect breast cancer. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In ... Services, Inc.’s Drug Benefit News (DBN) continues to ... reported in its Aug. 8 issue , CVS ... exclusion lists for 2015 each cut more drugs ... much savings these exclusions are likely to achieve. ...
(Date:9/17/2014)... 17, 2014 In a continuing effort ... Nile virus threats, Mosquito Shield of the South Shore ... with the Hanover Youth Athletic Association to treat area ... daily practices going until dusk, prime mosquito feeding time, ... athletes, coaches, and parents involved in outdoor athletic activities. ...
(Date:9/17/2014)... 17, 2014 According to new ... the leading global authority in medical device market ... regeneration market is expected to exceed $3.7 ... breast reconstruction, hernia repair, dural repair, vaginal slings, ... dental soft tissue regeneration. , Approximately 300,000 ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3
... March 10 Speaker Nancy Pelosi and Majority Whip James E. Clyburn held a photo opportunity this afternoon with representatives from the National Association of Public ... ... ... ...
... uncovered a mechanism for resistance to paclitaxel in ovarian ... chemotherapy resistance. Mohamed K. Hassan, Ph.D., a ... research as a collaborative study with his colleagues when ... in Egypt. Results of this study were presented at ...
... treating tumors with extreme heat or moderate heat may ... presented at the second AACR Dead Sea International Conference ... the Clinic, held March 7-10, 2010. "Low ... in curing both malignant and benign tumors using minimally ...
... , March 10 Omega Protein Corporation (NYSE: OME ), the nation,s leading producer of Omega-3 fish oil and specialty fish meal ... with net income of $12.6 million ( $0.69 per share) for the year ended December 31, 2008 . , ... ... ...
... 10 International Merchant Advisors, Inc. (PK: IMAI) ... announced today that the company is preparing to ... Organic Science, Inc.  Organic Science, Inc. is intended to become ... and is focused on the implementation of Organic,s  plans for ...
... March 10 As part of its continued focus on developing programs designed to meet employers, needs, Regence has acquired the assets of Kinetix Living Corp., ... ... , ... ...
Cached Medicine News:Health News:Pelosi Remarks at Photo Opportunity with the National Association of Public Hospitals 2Health News:Omega Protein Reports 2009 Results 2Health News:Omega Protein Reports 2009 Results 3Health News:Omega Protein Reports 2009 Results 4Health News:Omega Protein Reports 2009 Results 5Health News:Omega Protein Reports 2009 Results 6Health News:Omega Protein Reports 2009 Results 7Health News:Omega Protein Reports 2009 Results 8Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 2Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 3Health News:Regence Invests in Kinetix Living Corp. 2Health News:Regence Invests in Kinetix Living Corp. 3
... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
Medicine Products: